# OnCo record sodium-thiosulfate (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sodium-thiosulfate/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sodium-thiosulfate" ;
  schema:name "Sodium thiosulfate (otoprotectant)"@en ;
  schema:description "An old antidote proven in two paediatric trials to halve permanent hearing loss from cisplatin, and approved in 2022 as the first drug to prevent a chemotherapy side effect in children."@en ;
  schema:url <https://onco.cc/drugs/sodium-thiosulfate/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sodium_thiosulfate_(medical_use)> ;
  owl:sameAs <http://www.wikidata.org/entity/Q4457895> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1801109>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pedmark> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "supportive" ;
  onco:modality "Small-molecule chemoprotectant" ;
  schema:alternateName "Pedmark" ;
  onco:approval "US 2022: Reduce risk of ototoxicity from cisplatin in patients ≥1 month with localised, non-metastatic solid tumours", "EU 2023: Same" ;
  onco:cancers <https://onco.cc/cancers/hepatoblastoma/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:technologies <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:companies <https://onco.cc/companies/fennec-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct05382338/>, <https://onco.cc/trials/nct00716976/>, <https://onco.cc/trials/nct00652132/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-brock-n-engl-j-med/> .